Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s share price gapped up prior to trading on Monday . The stock had previously closed at $15.98, but opened at $17.06. Daiichi Sankyo shares last traded at $16.98, with a volume of 16,495 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Daiichi Sankyo has an average rating of “Hold”.

Daiichi Sankyo Trading Up 3.3%

The business has a 50-day moving average price of $16.28 and a two-hundred day moving average price of $18.35. The stock has a market capitalization of $31.67 billion, a P/E ratio of 18.09, a P/E/G ratio of 2.83 and a beta of -0.17. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.98 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.